Merger Announced
Research Alliance Corporation III and OHB Pediatrics Ltd. d/b/a Oak Hill Bio merger
Announced 27 Jul 2026
Advisers
- Target
- OHB Pediatrics Ltd. d/b/a Oak Hill Bio
- Acquirer
- Research Alliance Corporation III
- Target based in
- United States
- Buyer based in
- United States
- Amount raised
- US$175m
- Sector
- Biotech
- Tags
- Biotech, Rare Disease, Drug Development
In the league tables
Similar deals
- Werewolf Therapeutics and Ambros Therapeutics merger Aug 2026 · US$500m · Biotech
- BioMarin Pharmaceutical acquisition of Alesta Therapeutics Aug 2026 · US$275m · Biotech
- Jazz Pharmaceuticals acquisition of Actio Biosciences Aug 2026 · US$820m · Biotech
- Incyte acquisition of Vega Therapeutics Jun 2026 · US$1.3bn · Biotech
- Servier acquisition of Sevasemten and Edgewise muscular dystrophy business Jun 2026 · US$1.6bn · Biotech
Sources
- 27 Jul 2026 Press release (EX-99.1, exhibit), Oak Hill Bio and Research Alliance Corporation III Announce Business Combination Agreement to Create sec.gov
- 27 Jul 2026 Research Alliance Corporation III to Combine with Oak Hill Bio cooley.com
- 28 Jul 2026 Goodwin Advises Oak Hill Bio on $175 Million Business Combination Agreement With Research Alliance Corporation III to Create Publicly Listed Rare Disease Biotechnology Company goodwinlaw.com
